Insulet Corp PODD

Morningstar Rating
$137.92 −4.36 (3.06%)
View Full Chart

Company Report

Price vs Fair Value

PODD is trading at a LOCK|!zLVy$ premium.
Price
$137.92
Fair Value
LOCK|g?
Uncertainty
LOCK|@>#
1-Star Price
LOCK|!.?^Q
5-Star Price
TF$
Economic Moat
LOCK|$SCX%
Capital Allocation
LOCK|Fq@Zv^HF

Bulls Say, Bears Say

Bulls

Rumblings that Medicare's competitive bidding program for durable medical equipment distributors will include insulin pumps could boost Insulet, as its pumps are distributed through the pharmacy channel.

Bears

With only one product and low switching costs for customers, Insulet is vulnerable if larger competitors produce similar or superior tubeless insulin pumps.

News

Articles & Videos

Trading Information

Previous Close Price
$142.28
Day Range
$137.25142.69
52-Week Range
$126.40354.88
Bid/Ask
$137.92 / $140.61
Shares Outstanding
69.35M
Market Cap
$9.57B
Volume/Avg
2M / 2M

Key Statistics

Price/Earnings (Normalized)
23.50
Price/Sales
3.23
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
Total Yield
3.44%

Company Profile

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Growth
Total Number of Employees
5,400

Competitors

Valuation

Metric
PODD
ABT
DXCM
Price/Earnings (Normalized)
23.5020.0032.88
Price/Book Value
6.733.5612.08
Price/Sales
3.233.946.71
Price/Cash Flow
15.9816.8121.49
Price/Earnings
PODD
ABT
DXCM

Financial Strength

Metric
PODD
ABT
DXCM
Quick Ratio
1.510.971.37
Current Ratio
2.481.381.73
Interest Coverage
9.0410.4080.16
Quick Ratio
PODD
ABT
DXCM

Profitability

Metric
PODD
ABT
DXCM
Return on Assets (Normalized)
13.00%9.71%14.49%
Return on Equity (Normalized)
29.07%17.95%36.44%
Return on Invested Capital (Normalized)
17.78%13.03%20.31%
Return on Assets
PODD
ABT
DXCM

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|V@Nh^vSLOCK|?lQhw$182B
Medtronic PLC
MDT
LOCK|W$L^<$LOCK|P#g@$118B
Stryker Corp
SYK
LOCK|>%^bgTzLOCK|Jy>$106B
Boston Scientific Corp
BSX
LOCK|W%W<dMLOCK|y?&F&$65B
Edwards Lifesciences Corp
EW
LOCK|lFj!?@yMLOCK|HJ>&S$50B
DexCom Inc
DXCM
LOCK|W>JR&%KLOCK|f^@cV$32B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|$>bxCbwLOCK|N^$29B
Koninklijke Philips NV ADR
PHG
LOCK|McLOCK|?^$25B
Steris PLC
STE
LOCK|^<?Hy&LOCK|?Mw@$21B
Zimmer Biomet Holdings Inc
ZBH
LOCK|Q$rl&WdLOCK|z#!$18B

Sponsor Center